siltuximab
Sign in to saveAlso known as CNTO-328, CLLB8
Siltuximab (INN), sold under the brand name Sylvant, is used for the treatment of people with multicentric Castleman's disease. It is a chimeric (made from human and mouse proteins) monoclonal antibody that binds to interleukin-6. It is an interleukin-6 (IL-6) antagonist.
Research
344 papers- Siltuximab.2006
- Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.The Lancet. Oncology · 2014
- Siltuximab.2012
- Siltuximab in Idiopathic Multicentric Castleman Disease: Real-World Experience.Journal of hematology · 2024
- Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis.Blood advances · 2025
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has part
- carbon
- Has use
- medication
Show 5 more facts
- World Health Organisation international non-proprietary name
- siltuximab
- defined daily dose
- 37
- subject has role
- monoclonal antibody
- medical condition treated
- Castleman's disease
- has characteristic
- biopharmaceutical
via Wikidata · CC0
~3 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Side effects
- Drug interactions
- Mechanism of action
- History
- Research
- References
Siltuximab (INN), sold under the brand name Sylvant, is used for the treatment of people with multicentric Castleman's disease. It is a chimeric (made from human and mouse proteins) monoclonal antibody that binds to interleukin-6. It is an interleukin-6 (IL-6) antagonist.
The common adverse reactions include pruritus, increased weight, rash, hyperuricemia, and upper respiratory tract infection.
Excerpted from Wikipedia’s “siltuximab” article, available under the CC BY-SA 4.0 licence.